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Introduction: Epidermal growth factor receptor tyrosine kinase
inhibitors given concurrently with chemotherapy do not improve
patient outcomes compared with chemotherapy alone in advanced
non-small cell lung cancer (NSCLC). On the basis of preclinical
models, we hypothesized pharmacodynamic separation, achieved by
intermittent delivery of epidermal growth factor receptor tyrosine
kinase inhibitors intercalated with chemotherapy, as a reasonable
strategy to deliver combination therapy.
Methods: A phase I dose-escalating trial using two scheduling
strategies (arms A and B) was conducted in patients with advanced
solid tumors to determine the feasibility of intermittent erlotinib and
docetaxel. Phase II efficacy evaluation was conducted in an ex-
panded cohort of patients with previously treated advanced NSCLC
using arm B scheduling. Docetaxel was given every 21 days (70–75
mg/m2 intravenously) in both arms. In arm A, erlotinib was admin-
istered on days 2, 9, and 16 (600–1000 mg); in arm B, erlotinib was
delivered on days 2 through 16 (150–300 mg). Patients without
progression or unacceptable toxicity after six cycles continued
erlotinib alone.
Results: Eighty-one patients were enrolled in this study (17 arm A;
25 arm B; and 39 at phase II dose). Phase I patients had advanced
solid tumors and 22 with NSCLC (10 and 12 patients for arms A and
B, respectively). Treatment was well tolerated for both arms, with
dose-limiting toxicities including grade 3 infection and febrile neu-
tropenia in arm A (maximum tolerated dose [MTD] of erlotinib 600
mg/docetaxel 70 mg/m2) and grade 4 rash, febrile neutropenia, grade
3 mucositis, and grade 3 diarrhea in arm B (MTD of erlotinib 200
mg/docetaxel 70 mg/m2). The MTD for arm B was chosen for phase
II evaluation given the feasibility of administration, number of
responses (one complete response and three partial responses), and
achievement of pharmacodynamic separation. The response rate for
patients treated at the phase II dose was 28.2%, and the disease
control rate was 64.1%. Median progression-free and overall sur-
vival were 4.1 and 18.2 months, respectively. Common grade 3
toxicities were neutropenia (36%) and diarrhea (18%).
Conclusions: Pharmacodynamic separation using intercalated
schedules of erlotinib delivered on an intermittent basis together
with docetaxel chemotherapy is feasible and tolerable. Further
studies using this approach together with interrogation of relevant
molecular pathways are ongoing.
Key Words: Erlotinib, Docetaxel, Pharmacodynamic separation,
Non-small cell lung cancer, Phase II.
(J Thorac Oncol. 2011;6: 2112–2119)
Platinum-based chemotherapy has long been the standardof care for patients with advanced non-small cell lung
cancer (NSCLC). In recent years, new strategies integrating
molecular-targeted therapies have modified the treatment par-
adigm. Inhibition of the epidermal growth factor receptor
(EGFR) pathway with small molecule tyrosine kinase inhib-
itors (TKIs), such as erlotinib and gefitinib, was the first
targeted therapeutics to demonstrate efficacy as single agents
in NSCLC. A large phase III trial demonstrated a survival
advantage of erlotinib compared with placebo in the second-
or third-line setting.1 Importantly, this outcome was achieved
in an unselected patient population with no requirement for
tumor EGFR expression. Similarly, docetaxel chemotherapy
is a well-established second-line therapeutic option, which
has been shown to result in improved survival when com-
pared with placebo or other chemotherapeutic agents.2
Despite preclinical data suggesting that EGFR-TKIs
would have additive-to-synergistic effects when combined
with an array of chemotherapeutic agents, four large random-
ized phase III trials combining erlotinib or gefitinib together
with first-line platinum-based chemotherapy failed to in-
crease efficacy when compared with chemotherapy alone.3–6
Multiple possible explanations for these unexpected and dis-
appointing results have been offered, including lack of patient
selection, especially in view of the subsequent discovery of
activating mutations in EGFR. Alternatively, we have hy-
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pothesized a negative interaction between EGFR-TKIs and
chemotherapy in cancers with wild-type EGFR, which may
account for the lack of benefit of combination therapy in
previous phase III trials.7 Preclinical models suggest that
although EGFR-TKIs are cytotoxic in NSCLC cell lines
harboring EGFR-activating mutations, inducing apoptosis
through caspase-related mechanisms, they are primarily cy-
tostatic in EGFR wild-type cell lines.8,9 We and others have
shown evidence in support of sequence specificity and sched-
ule-dependent interactions of EGFR-TKIs and chemotherapy,
suggesting that strategies involving intermittent EGFR-TKI
dosing between chemotherapy cycles to achieve pharmaco-
dynamic separation might prove most efficacious.10–13 The
hypothesized explanation for this phenomenon exists in the
potential antagonism between targeted therapies and chemo-
therapy: EGFR-TKIs induce G1-phase cell-cycle arrest,
which protects cells from the cytotoxic effects of cell-cycle
phase-dependent chemotherapeutic agents.
To test this theory, we conducted a phase I/II study
designed to assess the safety and feasibility of two different
schedules intercalating intermittent erlotinib and docetaxel.
On the basis of the phase I data, a single dosing schedule was
used in the phase II efficacy evaluation.
PATIENTS AND METHODS
Patient Eligibility
Patients with histologically or cytologically confirmed
advanced solid tumors treated with any number of prior
chemotherapy regimens were eligible for the phase I portion
of the trial. Eligibility for the phase II portion consisted of
cytologically or histologically confirmed NSCLC, treated
with no greater than one previous treatment for metastatic
disease. Phase II patients must have had progressive or
recurrent disease after platinum-based chemotherapy. Prior
chemotherapy or radiotherapy must have been completed at
least 4 or 2 weeks, respectively, before study entry, and all
significant previous treatment-related toxicities had to be
resolved. Additional eligibility criteria included age older
than 18 years, life expectancy of more than 12 weeks, and an
Eastern Cooperative Oncology Group (ECOG) performance
status of 0 to 2 for phase I and ECOG performance status of
0 and 1 for phase II. Adequate hematologic (absolute neutro-
phil count 1500/l and platelet count 100,000/l), renal
(serum creatinine 1.5 mg/dl or a calculated creatinine
clearance50 ml/min), and hepatic function (serum bilirubin
less than or equal to the institutional upper limit of normal
and aspartate aminotransferases within 2.5 times the upper
limit of normal) were required. Patients with asymptomatic
treated brain metastasis (surgical resection or radiotherapy)
were eligible if they were neurologically stable and had
stopped taking steroids and/or anticonvulsants for a minimum
of 4 weeks. Patients who had previously received EGFR-
targeted therapy or docetaxel were excluded. Patients with
clinically significant ophthalmologic abnormalities or other
disorders that might increase the risk of corneal epithelial
injury were excluded. Patients with preexisting peripheral
neuropathygrade 2 or who were pregnant were not eligible.
Patients of childbearing potential were required to use a
medically acceptable contraceptive. For phase II, no prior
malignancy was allowed except for the following: adequately
treated basal cell or squamous cell carcinoma of the skin, in
situ cervical carcinoma, adequately treated stage I or II cancer
in complete remission, or any other malignancy from which
the patient had been disease-free for greater than 5 years. The
Institutional Review Board at the University of California,
Davis approved this study, which was conducted in accor-
dance with federal and institutional guidelines.
Study Design and Treatments
The phase I dose-escalation portion of the trial was
designed to determine feasibility, evaluate safety, and to
recommend a phase II dose and schedule of intercalation for
intermittent erlotinib and docetaxel. During the phase I por-
tion, patients were treated on one of the two independently
accruing treatment arms according to a predetermined dose-
escalation schema (Figure 1). Patients were enrolled using a
standard 3  3 design. Once accrual to the first dose level on
treatment arm A was completed, treatment arm B was open
for enrollment to its first dose level. Accrual was continued in
an alternating “ping-pong” fashion between both arms. Al-
though combined in a single trial, the intent was to simulate
concurrently run phase I trials.
 A 
Arm A Day 1 Day 2 Day 9 Day 16 Day 22 
Erlotinib*  X X X  
Docetaxel** X    X 
Arm B Day 1 Days 2 to 16 Days 17 to 21 Day 22 
Erlotinib  X    
Docetaxel** X    X 
*   Erlotinib: high-dose oral administration once weekly 
**  Docetaxel: intravenous infusion over 60 minutes 
 B 
Arm A* Erlotinib (mg) Docetaxel (mg/m2)
 07  006  1 
 07  008  2 
 07  0001  3 
 57  0001  4 
Arm B Erlotinib (mg) Docetaxel (mg/m2)
 07  051  1 
 07  002  2 
 57  002  3 
 57  052  4 
 57  003  5 
*The original dose escalation for arm A started at 1200 mg Erlotinib and 70 mg/m2 Docetaxel.  However, 
of five patients accrued at this level 2 experienced dose limiting toxicities, and the dose levels were 
revised. 
FIGURE 1. A, In the two phase I portions of the trial, do-
cetaxel was administered intravenously every 21 days. Treat-
ment arm A delivered erlotinib orally every week on days 2,
9, and 16, and in arm B, erlotinib was delivered on days 2
through 16. B, Phase I dose-escalation schemes for treat-
ment arms A and B.
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In arm A, docetaxel was administered intravenously on
day 1 of a 21-day cycle and erlotinib was given weekly on
days 2, 9, and 16. In arm B, docetaxel was given intrave-
nously on day 1of a 21-day cycle and erlotinib was given on
days 2 to 16. To decrease the frequency and severity of
known docetaxel-induced toxicities such as hypersensitivity
reaction, fluid retention, and cutaneous adverse events (AEs),
all patients received dexamethasone 4 or 8 mg orally twice
daily for 3 days, starting 12 to 24 hours before docetaxel
infusion. Erlotinib was taken orally in the morning with 200
ml of water 1 hour before or 2 hours after meals. Treatment
with both drugs continued in the absence of disease progres-
sion, provided patients were clinically benefiting and tolerat-
ing treatment. After six cycles of intermittent erlotinib and
docetaxel, patients were permitted to continue with erlotinib
monotherapy (Figure 1).
Three patients were treated per cohort for one cycle (21
days) with no intrapatient dose escalation. If no dose-limiting
toxicities (DLTs) were recorded, treatment continued and
three patients were treated in the subsequent cohort. How-
ever, if a patient developed a DLT, another three patients (for
a total of six) were treated within that cohort for one cycle. If
no additional DLTs were observed, dose escalation contin-
ued. Escalation was terminated when two or more patients
experienced DLT attributable to study drug at any given dose
level. DLT was defined as any of the following occurring
within the first cycle of treatment: grade 4 thrombocytopenia;
grade 3 thrombocytopenia associated with bleeding, transfu-
sion requirement, or lasting greater than 7 days; febrile
neutropenia or grade 4 neutropenia of greater than 7 days
duration; grade 3 peripheral neuropathy; or any grade 3
nonhematological toxicity considered by the investigator to
be clinically significant and related to study drug, except for
alopecia or inadequately treated nausea, vomiting, and/or
diarrhea. Toxicity was graded according to the National
Cancer Institute Common Toxicity Criteria version 2.0. The
maximum tolerated dose (MTD) was defined as the highest
dose level at which no more than one patient experienced
DLT when at least six patients were treated at that dose level
and were assessable for toxicity.
On the basis of the phase I multiple-dosing portion of
this study, treatment arm B dosing schedule was selected for
the phase II portion of this trial. Patients received 70 mg/m2
of intravenous docetaxel on day 1 and 200 mg of oral
erlotinib on days 2 through 16 of a 21-day cycle. Patients
without progression could receive a maximum of six cycles
of treatment and erlotinib monotherapy thereafter. Docetaxel
dose reductions were required for patients with significant
hematological or nonhematological toxicities in the preceding
cycle. Grade 3 peripheral neuropathy required removal
from the study. Erlotinib dose reductions were required for
intolerable grade 2 or grade3 cutaneous toxicity. Grade2
diarrhea and nausea/vomiting despite appropriate loperamide
or antiemetic use also required dose modification. Treatment
delay of more than 3 weeks because of toxicity required
removal of the patient from the study. Routine use of gran-
ulocyte colony-stimulating factors was permitted for the
phase II portion of the study in accordance with American
Society of Clinical Oncology guidelines.
Study Assessments
Baseline imaging and hematology plus blood chemistry
were obtained within 4 and 2 weeks of study entry, respec-
tively. Baseline screening included a complete medical his-
tory, physical examination, list of concomitant medications,
assessment of ECOG performance status, and body weight.
Weekly complete blood counts with white blood cell differ-
entiation were drawn, while blood chemistries were per-
formed before each 21-day cycle. Exploratory pharmacoki-
netic analyses were performed in a limited subset of patients.
AEs were evaluated on days 1 and 8 of the first cycle and
before each subsequent cycle using the National Cancer
Institute Common Toxicity Criteria version 2.0.
Tumor size was assessed through computed tomogra-
phy every 42 days. RECIST were used to determine tumor
response and disease progression. The primary objective of
the phase II portion was to determine response rate (RR) of
intermittent erlotinib combined with docetaxel when admin-
istered as second-line treatment in patients with advanced
NSCLC who previously received one platinum-containing
regimen. Progression-free survival (PFS), overall survival
(OS), and safety were secondary objectives. Patient archival
specimens and blood samples were submitted for exploratory
molecular analyses.
Statistical Analyses
For phase II, a one-stage design was used to test the
null hypothesis that objective RR did not exceed 5% at a 0.05
level of significance. Target accrual was 38 patients, to
provide 90% power to reject the null hypothesis if true
objective RR was 20%. With a sample size of 38 patients,
there was 90% certainty that at least one toxicity occurring as
much as 6% time would be captured. Kaplan-Meier methods
were used to determine PFS and OS.
RESULTS
Eighty-one patients were enrolled in this study. For
phase I, 17 patients were accrued to treatment arm A and 25
patients for treatment arm B. In the phase II portion of the
study, 39 patients with advanced NSCLC were treated. Base-
line demographics and disease characteristics are outlined in
Tables 1 and 2.
PHASE I
Dose Escalation
Treatment arm A. Five patients were accrued at the original
dose of 1200 mg of erlotinib weekly and 70 mg/m2 of
docetaxel, with two experiencing DLTs: one fatal sepsis and
one patient with pulmonary embolism. At a revised dose level
1, three patients were enrolled with one patient experiencing
DLT from febrile neutropenia (Table 3). An additional three
patients were accrued to dose level 1 without DLT. Dose
level 2 saw two of six patients with DLTs of febrile neutro-
penia and grade 3 infection. Although the MTD for treatment
arm A was established at the revised dose level 1 of 600 mg
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erlotinib weekly and 70 mg/m2 of docetaxel on day 1 of each
21-day cycle, this dose schedule was not considered feasible
for phase II evaluation.
Treatment arm B. One of three patients had a DLT of
febrile neutropenia at dose level 1, and an additional three
patients were enrolled at this dose level without DLT. Sub-
sequently, dose level 2 was opened and three patients were
treated without DLT. At dose level 5, two of three patients
experienced DLTs of grade 3 diarrhea and febrile neutrope-
nia. The dose level was de-escalated but, unexpectedly,
further DLTs were then observed in patients at dose level 4
(grade 3 mucositis and febrile neutropenia) and dose level 3
(grade 4 infection and febrile neutropenia). Hence, the MTD
for treatment arm B was established at dose level 2 of 200 mg
erlotinib on days 2 through 16 with 70 mg/m2 of docetaxel
day 1 of each 21-day cycle.
Antitumor Activity
Thirty-seven patients were evaluable for response in the
phase I portion of the trial. Twenty-one patients had NSCLC,
and 16 patients had other solid tumor malignancies. Five
patients were not evaluable for response and went off study
after one cycle without repeat disease assessment. Of the five
patients treated on arm A at the original dose level of 1200
mg erlotinib and 70 mg/m2 docetaxel, two patients with
advanced NSCLC had stable disease (SD) as best response.
Response data for patients with NSCLC are summarized in
Table 4. In treatment arm A, six patients had SD, three each
for dose levels 1 and 2. In treatment arm B, five patients had
SD (one each in dose levels 1, 2, and 4; two for dose level 3),
two had partial responses (PRs) (dose level 1), and a com-
plete response was also observed in one patient (dose level 2).
Response data for patients with solid tumors other than
NSCLC are summarized in Table 5. In arm A, SD was
observed in patients with primary unknown (dose level 1) and
prostate cancer (dose level 2). In arm B, two PRs were seen
in patients with hepatocellular and bladder cancer (dose level
2), and SD was observed in patients with small-cell lung
cancer (dose level 1), germ-cell malignancy (dose level 2),
ovarian cancer (dose level 3), and in a patient with adenoid
cystic cancer (dose level 4).
Toxicities
AEs for patients enrolled on treatment arms A and B
were similar. Common grade3 toxicities were hematologic,
with neutropenia occurring most often (Table 6). Nonhema-
tologic AEs were primarily grades 1 and 2 with rash, fatigue,
and diarrhea being the most common AEs. One patient
experienced grade 4 rash, and three patients experienced
grade 3 diarrhea.
TABLE 1. Phase I Baseline Patient and Disease
Characteristics of Patients Treated with Intermittent Erlotinib
and Docetaxela
Characteristics Arm A (n  17) Arm B (n  25)
Age (yr)
Median (range) 63 (40–75) 55 (34–83)
Age 65 11 19
Age 65 6 6
Sex
Female 6 14
Male 11 11
ECOG performance status
0 5 14
1 12 11
Race
African descent 1 0
White 15 23
East/South East Asian 1 2
Tumor type
NSCLC 10 12
Gallbladder 2 0
Prostate 1 1
Other 4b 12c
Prior chemotherapy regimens
Median (range) 1 (0–4)
a Phase I, arm A: erlotinib 600 to 800 mg d 2, 9, and 16 and docetaxel 70 mg/m2
d 1 on a 21-d cycle. Phase I, arm B: erlotinib 150 to 300 mg d 2 to 16 and docetaxel
70 to 75 mg/m2 d 1 on a 21-d cycle.
b Liposarcoma, primary unknown, pancreas, and esophageal cancer.
c Small-cell lung, duodenum, hepatocellular, rectal, breast, uterine papillary serous,
leimyosarcoma, adenoid cystic, ovarian, bladder, germ cell, and endometrial cancer.
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer.
TABLE 2. Phase II Baseline Patient and Disease
Characteristics of Patients with Advanced Non-small Cell
Lung Cancer Treated with Intermittent Erlotinib and
Docetaxela
Characteristics
No. of Patients
(N  39), %
Age (yr)
Median (range) 61 (38–80)
Age 65 24 (61.5)
Age 65 15 (38.5)
Sex
Female 24 (61.5)
Male 15 (38.5)
ECOG performance status
0 16 (41.0)
1 23 (59.0)
Race
African descent 2 (5.1)
White 35 (89.8)
East/South East Asian 2 (5.1)
Histological type
Adenocarcinoma 26 (66.7)
Squamous cell carcinoma 6 (15.4)
Other: NSCLC, NOS 7 (17.9)
Smoking status
Never smoker 11 (28.2)
Former/current smoker 28 (71.8)
a Phase II: erlotinib 200 mg d 2 to 16 and docetaxel 70 mg/m2 d 1 on a 21-d cycle.
ECOG, Eastern Cooperative Oncology Group; NSCLC, non-small cell lung cancer;
NOS, not otherwise specified.
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Erlotinib Pharmacokinetics
Nadir plasma concentrations of erlotinib and its pri-
mary metabolite (OSI-420) were assessed in five patients in
arm B, before their second cycle of docetaxel (day 21) to
ascertain if the goal of pharmacodynamic separation was
achieved.14 With this erlotinib dosing schedule of days 2
through 16, both erlotinib and OSI-420 were either undetect-
able (below limit of quantitation 1.00 ng/ml) or far below
therapeutic levels (estimated 183 ng/ml for wild-type EGFR
and 66 ng/ml for the L858R EGFR mutation) in four of five
cases sampled (Table 7).15 These subtherapeutic plasma con-
centrations prevent potential antagonism between erlotinib
and subsequent docetaxel dosing, supporting the concept of
pharmacodynamic separation. We have previously demon-
strated analogous findings using a similar intercalated design
with erlotinib and pemetrexed.16 In the one outlier (erlotinib
level 320 ng/ml), continued dosing of erlotinib beyond the
protocol-specified stop date is suspected.
Phase II
Treatment arm B was selected for further investigation
in the phase II portion of the study given the feasibility of
TABLE 3. Phase I Dose-Limiting Toxicities and Maximum
Tolerated Dose
N
No. of Patients
with DLTs Specific DLT MTD
Arm A dose level
1a 6 1 Febrile neutropenia b
2 6 2 Grade 3 infection
Febrile neutropenia
3 — —
4 — —
Arm B dose level
1 6 1 Febrile neutropenia
2 6 1 Grade 4 rash c
3 5 2 Grade 4 infection
Febrile neutropenia
4 5 2 Grade 3 mucositis
Febrile neutropenia
5 3 2 Grade 3 diarrhea
Febrile neutropenia
a Original dose level 1 for arm A was erlotinib 1200 mg d 2, 9, and 16 and docetaxel
70 mg/m2 on d 1 of a 21-d cycle. This dose was revised due to unacceptable toxicity.
b Phase I, arm A MTD: erlotinib 600 mg d 2, 9, and 16 and docetaxel 70 mg/m2 d
1 on a 21-d cycle.
c Phase I, arm B MTD: erlotinib 200 mg d 2 to 16 and docetaxel 70 mg/m2 d 1 on
a 21-d cycle.
DLT, dose-limiting toxicity; MTD, maximum tolerated dose.
TABLE 4. Phase I Response Data for Patients with NSCLC
Dose Level
No. of Patients (Best Response)
Arm Aa Arm B
1 3 (SD) 2 (PR); 1 (SD)
2 3 (SD) 2 (CR, SD)
3 — 2 (SD)
4 — 1 (SD)
5 — 0
a Stable disease observed in a single patient on arm A receiving original dose level
1 of erlotinib 1200 mg d 2, 9, and 16 and docetaxel 70 mg/m2 d 1 of a 21-d cycle.
CR, complete response; SD, stable disease; PR, partial response; NSCLC, non-
small cell lung cancer.
TABLE 5. Phase I Response Data for Patients with Tumors
Other than NSCLC
Dose
Level
No. of Patients (Best
Response: Tumor Type)
Arm A Arm B
1 1 (SD: primary
unknown)
1 (SD: SCLC)
2 1 (SD: prostate) 3 (PR: bladder; PR: hepatocellular;
SD, germ cell)
3 — 1 (SD, ovarian)
4 — 1 (SD, adenoid cystic)
5 — 0
SD, stable disease; PR, partial response; CR, complete response; SCLC, small cell
lung cancer; NSCLC, non-small cell lung cancer.
TABLE 6. Phase I Treatment-Related Adverse Events (Grade 3)
Adverse Eventa
Grade 3/4
Arm A (%) Arm B (%)
Hematologic
Neutropenia 10 (59) 16 (64)
Febrile neutropenia 3 (18)b 4 (16)
Hemoglobin — 1 (4)
Nonhematologic
Diarrhea — 3 (12)
Fatigue — 1 (4)
Infection (without neutropenia) 1 (6) 3 (12)
Mucositis — 1 (4)
Nausea 1 (6) —
Rash — 1 (4)
a Multiple occurrences of an adverse event in any one patient were recorded once
by the highest National Cancer Institute Common Toxicity Criteria grade.
b Grade 5 (fatal) neutropenic sepsis in one patient at original dose level 1 (erlotinib
1200 mg days 2, 9, and 16 and docetaxel 70 mg/m2 d 1).
TABLE 7. Trough Plasma Concentrations of Erlotinib and
OSI-420a
Sample Erlotinib (ng/ml)b OSI-420 (ng/ml)
1 BLOQc BLOQ
2 1.32 BLOQ
3 2.37 BLOQ
4 19.1 1.04
5 372 18.8
a Sample drawn on cycle 2, d 1 of arm B regimen of erlotinib d 2 to 16 and
docetaxel d 1 of a 21-d cycle.
b Erlotinib therapeutic efficacy, based on cellular inhibition of kinase activity IC50
values and correcting for plasma protein binding (95.9%), is estimated to be 183 ng/ml
for wild-type EGFR and 66 ng/ml for L858R EGFR mutation.15
c BLOQ 1.00 ng/ml.
BLOQ, below level of quantification; OSI-420, primary metabolite of erlotinib.
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administration, promising number of responses, and achieve-
ment of pharmacodynamic separation. Erlotinib 200 mg was
given daily for days 2 through 16, and docetaxel 70 mg/m2
was administered on day 1 of each 21-day cycle to 39 patients
with advanced NSCLC who had progressed after a platinum-
containing regimen.
Efficacy
Best response to therapy is shown in Table 8. The
overall RR was 28.1%, and the disease-control rate was
64.1%. Although most of patients did not have tissue avail-
able for EGFR mutation analysis, we tested circulating tumor
DNA in plasma for the presence of EGFR mutations.17 Two
of the patients with complete response and four of nine
patients with PR possessed EGFR mutations. Median PFS
was 4.1 months (Figure 2). The 1-year PFS was 17.9%.
Median OS was 18.2 months, and survival rates at 1 and 2
years were 58.9% and 38.5%, respectively (Figure 3).
Safety
Table 9 shows grade 3 treatment-related AEs for the
subset of patients treated at the phase II dose (n  39).
Anemia and thrombocytopenia were common, but these were
predominantly grade 1 or 2 toxicities with only one patient
experiencing grade 3 thrombocytopenia. Neutropenia was
common and occurred in 46% of patients and tended to be a
grade 3 or 4 toxicity (36%); four patients (10%) developed
febrile neutropenia. The most common nonhematological
toxicities (grade 1) were diarrhea (79%), rash (77%), and
fatigue (69%). Although 18% of patients had grade 3
diarrhea despite optimal preventative measures with lopera-
mide, supplemental fluids, and other supportive measures, no
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FIGURE 2. Phase II: Kaplan-Meier curve for progression-free
survival in patients with advanced non-small cell lung cancer
treated with oral erlotinib 200 mg days 2 through 16 and
intravenous docetaxel 70 mg/m2 day 1 of a 21-day cycle.
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FIGURE 3. Phase II: Kaplan-Meier curve for overall survival in
patients with advanced non-small cell lung cancer treated with
oral erlotinib, 200 mg days 2 through 16, and intravenous do-
cetaxel, 70 mg/m2 day 1 of a 21-day cycle.
TABLE 8. Tumor Response for Phase II Schedule of
Intermittent Erlotinib and Docetaxel
Response Parametera
Phase II Patients
(N  39) N (%)
CRb 2 (5.1)
PR 9 (23.1)
Overall response rate (CR  PR) 11 (28.2)
SD 14 (35.9)
Disease control rate (CR  PR  SD) 25 (64.1)
PD 12 (30.8)
Nonassessable 2 (5.1)
a Tumor assessments using Response Evaluation Criteria for Solid Tumors.
b EGFR mutations in two patients with CR; four patients with PR; three patients
with SD. EGFR mutations identified using Scorpion-amplification refractory mutation
system of circulating tumor DNA in plasma.17
CR, complete response; PD, progressive disease; PR, partial response; SD, stable
disease.
TABLE 9. Phase II Treatment-Related Adverse Events
(Grade 3)
Adverse Eventa Grade 3/4, N (%)
Hematologic
Neutropenia 14 (36)
Febrile neutropenia 4 (10)
Platelets 1 (3)
Nonhematologic
Diarrhea 7 (18)
Dehydration 2 (5)
Fatigue 2 (5)
Hypokalemia 1 (3)
Hyponatremia 1 (3)
Infection (without neutropenia) 1 (3)
Myalgias 1 (3)
Nausea 1 (3)
Ocular 1 (3)
Pain 1 (3)
Stomatitis 1 (3)
a Multiple occurrences of an adverse event in any one patient were recorded once
by the highest National Cancer Institute Common Toxicity Criteria grade.
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patient experienced a grade 3 rash. The most common AEs
resulting in dose reduction were diarrhea or intolerable grade
2 rash. There were no treatment-related deaths on the phase II
portion of this study.
DISCUSSION
Chemotherapy plays a crucial role in the treatment of
most stages of NSCLC. Likewise, agents targeting the EGFR,
particularly the TKIs, erlotinib and gefitinib, have proven
their importance in the treatment paradigm for advanced
NSCLC. Erlotinib is approved for second- and third-line
therapies, and, now, in the era of personalized medicine,
first-line EGFR-TKI treatment is considered a standard of
care for patients with cancers possessing an EGFR muta-
tion.1,18–20 Although the appeal of combining traditional cy-
totoxic chemotherapy with biological therapeutics is under-
standable, four large randomized phase III trials of
chemotherapy with or without an EGFR-TKI in patients with
unselected advanced NSCLC did not demonstrate improve-
ment in clinical outcomes.3–6 Moreover, combinations of
chemotherapy and other “targeted” small-molecule inhibitors
have generally been unsuccessful in NSCLC. In contrast,
monoclonal antibodies such as bevacizumab and cetuximab
have shown improved efficacy when combined with chemo-
therapy, perhaps because of inherent differences in mecha-
nisms of action.21–23
In this study, we report a phase I/II trial exploring a
combination strategy based on pharmacodynamic parameters
together with supporting preclinical data. We and others have
previously reported that pretreatment with erlotinib can result
in a G1 arrest, abrogating the cytotoxicity of cell-cycle-
specific chemotherapy.8,24 In our studies, a sequence of
M-phase-specific docetaxel followed by erlotinib exhibited
the greatest levels of apoptosis and was superior to the
reverse sequence (erlotinib followed by docetaxel). We
hypothesized that to extend these observations to the
clinic, an erlotinib dose schedule intercalating intermittent
delivery between docetaxel cycles would attain pharmaco-
dynamic separation, abrogating negative cell-cycle-spe-
cific interactions of these agents.
Two erlotinib dose schedules were used in the phase I
portion of this trial. Treatment arm A used high-dose erlotinib
administered weekly with docetaxel. Weekly erlotinib at
doses 600 mg result in high peak plasma levels within 4
hours.25 With a half-life of 36 hours, plasma levels from
weekly therapy would be expected to be undetectable before
the end of the 8-day intercalated dosing interval, allowing
pharmacodynamic separation from subsequent docetaxel ad-
ministration. In our trial, patients in arm A were unable to
tolerate a weekly dose higher than 600 mg together with
docetaxel 70 mg/m2, a cumulative erlotinib dose considerably
lower than that which could be given in arm B (MTD,
erlotinib 200 mg days 2 through 16 and docetaxel 70 mg/m2).
Thus, the arm B schedule was chosen for further phase II
efficacy evaluation.
For phase II, 39 patients with advanced NSCLC who
had progressed after a platinum-containing regimen were
treated with erlotinib 200 mg days 2 through 16 and docetaxel
70 mg/m2 day 1 on a 21-day cycle. Overall RR was 28.1%
and disease-control rate was 64.1%. Encouragingly, median
PFS was 4.1 months and OS was 18.2 months. In comparison,
the BR.21 phase III trial demonstrated that patients with
advanced NSCLC treated with erlotinib monotherapy after
failing one or two prior chemotherapy regimens had a RR of
8.9% and median PFS and OS of 2.2 months and 6.7 months,
respectively.1 Docetaxel, as second-line therapy, showed a
median survival of 7.0 months in the TAX 317 trial.2 Al-
though our results cannot be directly compared with the phase
III trials described earlier in the text, the response and
survival outcomes are favorable.
As previously described, EGFR-activating mutations
were identified by means of an allele-specific polymerase
chain reaction assay (Scorpion-amplification refractory mu-
tation system) of circulating DNA in plasma in some patients
on this trial.17 The presence of an EGFR mutation correlated
significantly with improved tumor response and PFS in pa-
tients with NSCLC treated with intermittent erlotinib and
docetaxel. However, the use of docetaxel in this intercalated
schedule did not seem to reduce erlotinib activity in patients
possessing EGFR mutations. In addition, patients with wild-
type EGFR also showed benefit.
In conclusion, this study describes clinical applica-
tion of a model of pharmacodynamic separation designed
to overcome hypothesized negative interactions of concur-
rent administration of erlotinib and chemotherapy. Others
have recently reported using this approach to administer
EGFR-TKIs and other chemotherapeutic regimens. For ex-
ample, in the FASTACT trial, Mok et al.26 demonstrated
improved RR and PFS in patients receiving intercalated
gefitinib plus gemcitabine-carboplatin versus those random-
ized to chemotherapy alone. A sequential approach of
administering chemotherapy before therapy with an
EGFR-TKI is a potential alternative design of overcoming
antagonism. One such study, SATURN, showed an im-
provement in survival in an unselected population of
patients demonstrating disease control after treatment with
four cycles of platinum agent-based chemotherapy fol-
lowed by erlotinib. Whether an intercalated or sequential
model is more efficacious in achieving pharmacodynamic
separation will require further exploration.27
Considering the inherent myelosuppression associated
with docetaxel in previously treated patients, in our own
studies in second-line therapy for NSCLC, we are currently
evaluating a similar strategy with intercalated erlotinib and
pemetrexed.16 Further studies exploring pharmacodynamic
separation are ongoing.
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